AMLX
Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals (AMLX) Q2 2026 earnings
Published Aug 6, 2026
AI summary
- GAAP EPS −$0.39, up from −$0.46 a year ago.
- Amylyx reported a net loss of $43.4 million for the second quarter of 2026.
- The company completed the final study visit for its Phase 3 LUCIDITY trial of avexitide.
- Topline data for the LUCIDITY trial is expected in late August or early September 2026.
- Cash and cash equivalents totaled $250.8 million, with a runway expected into 2028.
Results vs analyst consensus
Revenue
Not reported in this release.
EPS · GAAP
Reported · GAAP diluted EPS
−$0.39
Consensus not captured before release
Prior year: −$0.46
Consensus: Yahoo Finance · Q2 2026
Revenue display rounded; difference uses exact result.
Next quarter outlook
No guidance in this release.
What to watch
- The company is currently in a pre-commercial stage and reported no revenue for the quarter.
- Operating expenses increased due to higher legal costs and commercial strategic investments.
Read original report
Source: Amylyx Pharmaceuticals, Inc. press release · SEC Form 8-K exhibit 99.1